2023 annual financial data
Seres Therapeutics 2023 Operating margin
Direct answer
Operating margin was -154.44%.
Operating income was -195,097,000 USD and net income was -113,724,000 USD.
Operating cash flow was -117,354,000 USD.
Get free Seres Therapeutics email updates.
Bullstory sends one daily email when new analysis or important company news is available.
Verified data
- Revenue
- 126,325,000 USD
- Operating income
- -195,097,000 USD
- Net income
- -113,724,000 USD
- Operating cash flow
- -117,354,000 USD